Overview

The Bioavailability of Rifampicin in (FDCs) Widely Used in South Africa to Treat Drug-susceptible (TB)

Status:
Completed
Trial end date:
2017-02-01
Target enrollment:
Participant gender:
Summary
3-way cross-over single dose design evaluating bioavailability of 2 rifampicin-containing FDCs vs a single drug comparator in healthy volunteers
Phase:
Phase 1
Details
Lead Sponsor:
University of Cape Town
Treatments:
Isoniazid
Rifampin